Supplemental Figure 2 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy

Q: What type of study is this?

This is a Quantitative Study study.

Howard L. Li; Soren Charmsaz; Mari Nakazawa; Stephanie Alden; Madelena Brancati; James M. Leatherman; Ervin Griffin; Hua‐Ling Tsai; Nicole Groß; Christopher J. Thoburn; Alexei Hernandez; Erin M. Coyne; Sarah M. Shin; Royce P. Lee; Evan J. Lipson; Burles A. Johnson; Aliyah Pabani; Yasser Ged; Marina Baretti; Julie R. Brahmer; Jean Hoffman‐Censits; Tanguy Y. Seiwert; Daniel J. Zabransky; Jennifer N. Durham; Elizabeth M. Jaffee; G. Scott Chandler; Brittany L. Adler; Won Jin Ho; Chester Kao; Mark Yarchoan

doi:10.1158/2767-9764.30256041

Key Points

Th1 cytokine IFN-gamma remains significantly associated with fatigue in cancer, indicating immune system involvement.
Patients receiving immune checkpoint inhibitor therapy have distinct immune activation profiles linked to fatigue, highlighting potential biomarkers.
Analysis involved excluding patients undergoing combined chemotherapy, using the Wilcoxon Rank-Sum Test for statistical significance.
Further research should explore how immune factors contribute to fatigue, given the therapeutic implications and patient quality of life.

Implication

Analysis shows significant Th1 cytokine changes in cancer patients, suggesting immune factors play a role in fatigue.

Abstract

Supplemental Figure 2. Early-on-treatment Log2 Fold Change Differences After Excluding Patients Receiving ICI + Chemotherapy/Anti-VEGF. Th1 cytokine, (A) IFN-gamma, remains significant after excluding patients who received ICI + Chemo/Anti-VEGF therapy. Wilcoxon Rank-Sum Test, *p<0.05.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a217d2 https://doi.org/10.1158/2767-9764.30256041

View Full Paper

Ask AI

Bookmark

Share

Supplemental Figure 2 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplemental Figure 2 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading